A 48-year-old woman with a 10-year history of essential hypertension on amlodipine 5 mg daily presents with fatigue and dyspnea on exertion. Her blood pressure is 165/105 mmHg. Laboratory tests show: serum sodium 128 mEq/L, serum osmolality 265 mOsm/kg, urine osmolality 580 mOsm/kg, and urine sodium 65 mEq/L. Plasma renin activity is elevated at 4.2 ng/mL/hr (normal 0.5–1.6). What is the most likely explanation for her hypertension and hyponatremia?

Explanation

## Clinical Diagnosis This patient presents with **resistant hypertension** (BP 165/105 on amlodipine) with **hyponatremia and SIADH** (low serum osmolality, high urine osmolality, high urine sodium despite low serum sodium). ## Key Laboratory Findings **High-Yield:** The constellation of findings points to **secondary hyperaldosteronism with concurrent SIADH**: | Finding | Interpretation | |---------|----------------| | Elevated plasma renin activity (4.2) | RAAS activation → secondary hyperaldosteronism | | Serum sodium 128 (low) | Hyponatremia | | Serum osmolality 265 (low) | Hypoosmolality | | Urine osmolality 580 (high) | Kidney concentrating urine despite low serum osmolality = SIADH | | Urine sodium 65 (high) | Aldosterone-mediated sodium retention is overwhelmed by vasopressin-induced water retention | ## Pathophysiology: RAAS Activation → SIADH **Key Point:** In resistant hypertension with RAAS activation, elevated angiotensin II stimulates **both** aldosterone secretion AND vasopressin (ADH) release from the posterior pituitary. ```mermaid flowchart TD A[Resistant Hypertension<br/>Renal Hypoperfusion]:::outcome --> B[Renin Release]:::action B --> C[Angiotensin II Formation]:::outcome C --> D[Aldosterone Secretion]:::action C --> E[Vasopressin ADH Release]:::action D --> F[Sodium Reabsorption<br/>K+ Wasting]:::outcome E --> G[Water Reabsorption<br/>Dilutional Hyponatremia]:::outcome G --> H[SIADH Pattern<br/>Low Na, High Uosm]:::outcome F --> I[Hypokalemia]:::outcome ``` ### Why SIADH Develops in This Setting 1. **Angiotensin II directly stimulates vasopressin secretion** from the supraoptic and paraventricular nuclei 2. **Non-osmotic stimuli override osmotic inhibition** — even though serum osmolality is low (which should suppress ADH), the presence of elevated Ang II maintains ADH secretion 3. **Result:** Kidney continues to reabsorb water despite hypoosmolality → dilutional hyponatremia **Clinical Pearl:** This is a form of **"secondary SIADH"** — not primary SIADH from CNS disease or malignancy, but SIADH induced by Ang II-mediated non-osmotic stimulation of vasopressin. ## Why This Is Secondary (Not Primary) Hyperaldosteronism **Mnemonic: RAA** — **R**enin **A**ctivation drives **A**ldosterone (secondary), not primary aldosterone excess - **Elevated renin activity** (4.2) indicates the kidney is sensing hypoperfusion and activating RAAS - In primary hyperaldosteronism, renin would be **suppressed** (negative feedback) - This patient's hypertension is driving RAAS activation, not autonomous aldosterone secretion ## Differential Diagnosis | Condition | Plasma Renin | Aldosterone | Vasopressin | Serum Na | |-----------|--------------|-------------|-------------|----------| | **Secondary HA + SIADH** (this case) | **↑ (4.2)** | ↑ | ↑ | **↓ (128)** | | Primary hyperaldosteronism | ↓ (suppressed) | ↑ | Normal | Normal or ↑ | | Primary SIADH | Normal | Normal | ↑ | ↓ | | Diuretic-induced hypokalemia | ↑ | ↑ | Normal | Normal | | Hypothyroidism | Normal | Normal | Normal | Normal or ↓ | ## Treatment Approach **Key Point:** Management requires addressing both components: 1. **RAAS inhibition:** ACE inhibitor or ARB (not already on one — currently on amlodipine alone) 2. **Vasopressin antagonism:** Fluid restriction or vaptans if severe 3. Avoid loop diuretics (would worsen RAAS activation) **High-Yield:** Adding an ACE inhibitor or ARB would suppress Ang II → reduce both aldosterone AND vasopressin → improve both hypertension and hyponatremia.